Testosterone Efficacious for Correcting Anemia in Middle-Aged Men
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 30, 2023 -- Testosterone replacement therapy (TRT) is efficacious for correcting anemia among middle-aged and older men with hypogonadism and anemia, according to a study published online Oct. 27 in JAMA Network Open.
Karol M. Pencina, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues examined the efficacy of TRT for correcting anemia in men with hypogonadism and anemia in a placebo-controlled trial conducted at 316 U.S. sites. A total of 5,204 eligible men aged 45 to 80 years with hypogonadal symptoms and cardiovascular disease or increased cardiovascular disease risk were included: 815 with anemia and 4,379 without anemia.
The researchers found that compared with placebo-treated men, a significantly greater proportion of testosterone-treated men had corrected anemia at six months (41.0 versus 27.5 percent), 12 months (45.0 versus 33.9 percent), 24 months (42.8 versus 30.9 percent), 36 months (43.5 versus 33.2 percent), and 48 months (44.6 versus 39.2 percent). A significantly smaller proportion of testosterone- versus placebo-treated men developed anemia among the participants without anemia. There was an association seen for changes in hemoglobin with changes in energy level.
"In middle-aged and older men with hypogonadism and anemia, TRT was more efficacious than placebo in correcting anemia," the authors write. "TRT was also associated with a reduced incidence of anemia among men without anemia at baseline."
Several authors disclosed ties to the pharmaceutical industry; one author reported holding a patent for a free testosterone calculator.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Iptacopan Improves Hematologic, Clinical Outcomes in Persistent Anemia
TUESDAY, March 19, 2024 -- The first-in-class oral factor B inhibitor iptacopan improves hematologic and clinical outcomes in anti-C5-treated patients with persistent anemia and...
Testosterone Treatment Does Not Cut Fracture Incidence in Men With Hypogonadism
THURSDAY, Jan. 18, 2024 -- Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a...
AHA: No Real Benefit Seen for Liberal Transfusion Strategy in AMI, Anemia
TUESDAY, Nov. 14, 2023 -- For patients with acute myocardial infarction and anemia, a liberal transfusion strategy does not significantly reduce the risk for recurrent myocardial...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.